Labcorp acquires women's digital health firm Ovia

By LabPulse.com staff writers

August 13, 2021 -- Labcorp announced it has acquired digital health firm Ovia Health in a move the company said aims to improve patient experience and reduce healthcare costs in relation to women's health.

Ovia has developed a software platform designed to help individuals manage parenting and women's and family health. It includes features like reproductive cycle tracking, baby growth tracking, and fertility and pregnancy support.

Ovia offers the platform to individuals, employers, and health plans. The company generates $20 million in annual revenues and has supported over 15 million family journeys.

Labcorp believes that Ovia's offerings will fit well with its own specialty testing services and expertise in diagnostics and genetics in women's health. Labcorp noted that it already supports Ob-Gyn and primary care doctors with testing, screening, educational support, and clinical trial services for women, including women who are expecting.

The acquisition stems from talks that began in the past year between the two companies, following a strategic investment from Labcorp's Venture Fund in August 2020.

Specific transaction terms were not disclosed.

Labcorp deploys new SARS-CoV-2 sequencing panel
Labcorp will start using Molecular Loop Biosciences' SARS-CoV-2 research sequencing panel to sequence thousands of complete coronavirus genomes each week...
OmniSeq, Labcorp launch new oncology test
OmniSeq and Labcorp have launched OmniSeq Insight, a new test based on next-generation sequencing that's intended to help improve oncology treatment and...
Labcorp to buy intellectual property from Myriad Genetics
Labcorp plans to buy some of Myriad Genetics' operating assets and intellectual property from its autoimmune business unit, including its Vectra rheumatoid...
Labcorp adds new COVID-19 antigen test to repertoire
Labcorp has added a new high sensitivity antigen test for screening for active COVID-19 disease to its testing offerings. The nasal swab test was developed...
CDC awards Labcorp SARS-CoV-2 sequencing contract
The U.S. Centers for Disease Control and Prevention (CDC) has awarded Labcorp a contract to provide genomic sequencing of samples of the SARS-CoV-2 virus.

Copyright © 2021 LabPulse.com

Last Updated bc 8/13/2021 10:30:20 AM